Biologics Quality Control Testing

ABOUT US

PathoQuest, a spin-out of Institut Pasteur Paris, is a genomics expert company offering a game-changing next-generation sequencing (NGS) approach for microbiology testing.

The NGS-based technology the company has developed is used for:

• The quality control (QC) testing of biologicals (e.g., ATMP, vaccines, antibodies), enabling rapid and robust analysis at a GLP and GMP level

PathoQuest’s technology leverages the company’s proprietary sample preparation protocols, which are applicable to several types of biological samples, proprietary internally-curated pathogen genome databases, and automated analysis pipelines.

LATEST NEWS

PathoQuest Appoints Sébastien Renouf, Pharm D., as Chief Pharmaceutical Officer

PathoQuest Appoints Sébastien Renouf, Pharm D., as Chief Pharmaceutical Officer

Dr. Sébastien Renouf has 20 years of experience in Regulatory Affairs, Quality Assurance, and Safety Control for Cell & Gene Therapy. Before joining PathoQuest, Dr. Renouf was Chief Pharmaceutical Officer at CELLforCURE a CDMO specialized in the CART Cells manufacturing and part of the Novartis Group, where he supported the implementation of inspection and marketing authorization accreditation processes.

read more
PathoQuest Receives GMP Certification for its NGS-based Quality Control Testing Services

PathoQuest Receives GMP Certification for its NGS-based Quality Control Testing Services

We are glad to announce today that PathoQuest has obtained a GMP certificate for its quality control testing activities at its French-based facilities in Paris (France), following a recent inspection by the French National Agency for the Safety of Medicine and Health Products (ANSM). PathoQuest is the first French CRO to offer GMP grade NGS-based testing services to assess the quality control of Human Medicinal Products and Human Investigational Medicinal Products.

read more
PathoQuest closes up to €15 million Series B financing round led by growth investor SHS Capital

PathoQuest closes up to €15 million Series B financing round led by growth investor SHS Capital

PathoQuesttoday announced the closing of a financing round up to €15M. This funding leverages the NGS technology in a proprietary approach to assess the viral safety and genetic characterization of biologics. It will support the development of PathoQuest’s US site (Wayne, PA), the expansion of the portfolio of NGS-based quality control (QC) tests and will accelerate its growth and market share worldwide.

read more
w

Let’s Start Something New

Welcome to PathoQuest!